Physician Sentiment on ENHERTU®

Compiled and reviewed by the KOL Pulse research team, led by Brian Shields, Founder, KOL Pulse. Last updated 2026-07-13. KOL Pulse reports the physician conversation and does not endorse any product.

Trial 1 · NCT04784715

What do oncologists think of the DESTINY-Breast09 trial (ENHERTU®)?

DESTINY-Breast09 — 1L HER2-positive metastatic breast cancer (T-DXd + pertuzumab)

FDA APPROVED · Dec 2025FDA-approved December 15, 2025, in combination with pertuzumab for first-line unresectable or metastatic HER2-positive breast cancer.

Physicians are broadly favorable, with real nuance on DESTINY-Breast09: 43% of 44 verified physician voices positive, 21% nuanced (praising the result while flagging a caveat), 36% neutral, 0% critical.

43%

21%

36%

Positive 43% Nuanced 21% Neutral 36% Critical 0%

Denominator: 44 distinct verified physician voices across 123 oncologist posts, 2025-04-21 to 2026-06-01. Sponsor: Daiichi Sankyo (with AstraZeneca)

See full DESTINY-Breast09 conference coverage & trial data →

Primary sources: ClinicalTrials.gov · NCT04784715 · FDA — DESTINY-Breast09 approval (Dec 2025)

FDA approval (Dec 15, 2025): fam-trastuzumab deruxtecan-nxki with pertuzumab for first-line unresectable or metastatic HER2-positive breast cancer (based on DESTINY-Breast09, NCT04784715).

Physician voices — verbatim

Representative positive voice

ADCs are rapidly moving to earlier line treatment for breast cancer. Will likely reach the (neo)adjuvant setting soon. Here’s a recap of key ADC phase 3 trials expected to shape practice in the next future:

Paolo Tarantino

@PTarantinoMD

Representative nuanced voice

On DESTINIY-Breast09 before #ASCO25 The announcement of DB-09 in April 2025, showing a significant PFS advantage of T-DXd + pertuzumab over THP in HER2+ metastatic breast cancer, has generated great excitement. However, ahead of the full data presentation at ASCO 2025, several

Yakup Ergün

@dr_yakupergun

Full physician voice list (44)

Physician	Comment (verbatim)	Sentiment	Impressions
Paolo Tarantino @PTarantinoMD	ADCs are rapidly moving to earlier line treatment for breast cancer. Will likely reach the (neo)adjuvant setting soon. Here’s a recap of key ADC phase 3 trials expected to shape practice in the next future:	Positive	38,686
Dr Amol Akhade @SuyogCancer	Another money 💰 slide from #asco25 @ASCO . Treatment algorithm for HR +/ HER 2 -ve mBC @OncoAlert @medicalwatchBC	Neutral	33,619
Tatiana Prowell, MD @tmprowell	#OncTwitter #regulatory #bcsm 📣 #FDA has approved trastuzumab deruxtecan + pertuzumab for 1st-line tx of adults w/ HER2+ unresectable or #MetastaticBreastCancer based on DB-09 trial: 🏆44% ⬇️ in risk of progression/death vs THP (mPFS: 40…	Positive	22,903
Dr Sarah Sammons @drsarahsam	Destiny-Breast-09 will likely establish a new first-line therapy for HER2+ MBC. Here are my considerations going into #ASCO25 Patient population considerations: 1) De novo patients (capped at 50%): these patients are more likely to respon…	Neutral	15,289
Erika Hamilton, MD, FASCO @ErikaHamilton9	T-DXd + pertuzumab approved for 1st L HER-2+ #bcsm! Now for the debates around induction length, maintenance, re-induction etc. My opinion: I'll induce to maximal patient response (this will likely be longer than 6 cycles), then move to m…	Neutral	15,114
Matteo Lambertini, MD PhD @matteolambe	No comments needed 🤩🥳😍 congrats super @stolaney1 from @DanaFarber and all involved in the #DB09 trial !!!! #ASCO25 @OncoAlert @ASCO @DFCI_BreastOnc	Positive	13,645
Sara Tolaney @stolaney1	A lot is happening in breast cancer! ASCENT-04 reports improvement in PFS for sacituzumab + pembro vs TPC+pembro in 1L mTNBC, & DESTINY-Breast09 reports improved PFS for TDXd+P vs THP in 1L metastatic HER2+ breast cancer! Nice to see new …	Positive	12,987
Yakup Ergün @dr_yakupergun	On DESTINIY-Breast09 before #ASCO25 The announcement of DB-09 in April 2025, showing a significant PFS advantage of T-DXd + pertuzumab over THP in HER2+ metastatic breast cancer, has generated great excitement. However, ahead of the full d…	Nuanced	11,790
Oncology Brothers @OncBrothers	Day 4 #ASCO25 Highlights: 1. #DestinyBreast09: 1L TDXd Her2+ MBC 2. #SOFT/TEXT: Adj endo breast ca 3. #CM816: NeoAdj Nivo/chemo NSCLC 4. #NeoADAURA: NeoAdj Osi mEGFR NSCLC 5. #DeLLphi304: 2L Tarla SCLC 6. #IMForte: 1L maint Lurbi ES-…	Neutral	10,902
Harold J. Burstein, MD, PhD, FASCO @DrHBurstein	Thematic take on @ASCO breast cancer abstracts: 1. Move 'em up. DB09, ASCENT-04, SERENA-6 are really just trials of using agents earlier in the course of advanced disease. Since all patients with the right tumor subtype will eventually g…	Neutral	8,348
Tom Powles @tompowles1	Two ADC/PD1 combinations show +ve efficacy in 1st line breast cancer. ASCENT-04: sacituzumab/pembro vs TPC/pembro in mTNBC =⬆️ PFS & DESTINY-B09 TDXD/Pembro vs THP in HER2+ ⬆️PFS. Topo-1:TROP2/PD1 ADC/IO combos struggled in bladder cancer. …	Positive	6,778
Stephanie Graff, MD, FACP, FASCO @DrSGraff	My take: ▫️Many pts do well w/1L THP > HP w/maintenance tucatinib in HR- and palbo in HR+ ▫️DB-09 may be preferred in pts w/ bulky disease, PIK3CA alterations, or HER2 heterogeneity, brisk relapse We need 🔎 DB09 maintenance option 🧰prognos…	Neutral	4,756
Kazuki Nozawa, MD @kazuki_nozawa	T-DXd moves toward 1st-line standard for HER2+ MBC; DESTINY-Breast09 results are out in a press release—significant PFS improvement with pertuzumab combo! OS data is still immature at this interim analysis. Will we see the full results at …	Nuanced	4,062
Kristina Jankovic, MD @JankovicK	🆕🆕🆕🆕🆕🆕🆕🆕🆕🆕🆕🆕 DESTINY-Breast09: ☄️ Enhertu + pertuzumab shows superior PFS 🆚 THP in 1L HER2+ mBC — first regimen in over a decade to outperform SoC Data to be presented at an upcoming medical meeting. 📈🔜 🔗 https://t.co/0rtXqJa2YZ @OncoAl…	Neutral	3,667
Aya Mohamed \| MSc, MD 🎗 @Dr_Oncologista	DESTINY-Breast09 T-DXd + Pertuzumab defines a new depth-driven paradigm in 1L HER2+ metastatic breast cancer: >50% achieve CR/Deep PR (≥80% tumor reduction) with progressively deepening responses over ~9 – 24 months. @OncoAlert #ASCO26 @…	Neutral	2,910
Elisa Agostinetto @ElisaAgostinett	As expected, DB-09 showed significant improvement in PFS with T-DXd in 1️⃣st line in combination with pertuzumab, thus likely representing a practice-changing study for HER2+ #breastcancer Looking forward to seeing the data that will be p…	Positive	2,714
Toni Choueiri, MD @DrChoueiri	📢 #ASCO25 \| DESTINY‑Breast09 LBA1008 \| 1L HER2+ a/mBC: T‑DXd + P vs THP—median PFS 40.7 mo vs 26.9 mo (HR 0.56; P < .00001); safety profile similar with ILD rates ~ 10% vs 3%. Practice changing work by Sara M. Tolaney et al. Full abstract →	Positive	2,711
Gil Morgan, MD @weoncologists	DESTINYBREAST-09 shows PFS improvement with T-DXd in 1️⃣st line in combo with pertuzumab #BreastCancer News From Industry: Source AstraZeneca	Neutral	2,556
𝐂𝐡𝐚𝐧𝐝𝐥𝐞𝐫 𝐏𝐚𝐫𝐤 𝐌𝐃 𝐅𝐀𝐂𝐏 @CParkMD	⭐️Congratulations to Dr. Sara Tolaney @stolaney1 @DanaFarber and the #DestinyBreast09 investigators for a TRANSFORMATIVE study for 1st line metastatic HER2+ breast cancer. #ASCO25 Really enjoyed talking to Dr. Giuseppe Curigliano on the …	Positive	2,430
Gaia Griguolo @GaiaGriguolo	#ASCO25 DESTINY-Breast09 @stolaney1 First-line T-DXd+P vs THP significantly prolongs PFS: 40.7 vs 26.9 mos Benefit seen across subgroups OS not mature PFS2 benefit (10% received T-DXd after THP) @OncoAlert	Nuanced	1,898
Nicole Casasanta, MD @ncasasanta	8/21 #TumorBoardTuesday #bcsm 🧑‍🏫Mini Tweetorial 4🧑‍🏫 📍PROs DB-09📍 T-DXd+P vs THP > diarrhea, N/V, const, appetite loss THP > skin mucosis sx Overall tx tolerability C1-9 similar, waiting more data ➡️ T-DXd + P appears more toxic Are we ass…	Nuanced	1,848
Jame Abraham, MD, FACP @jamecancerdoc	Enhertu + Pertuzumab show superiority in progression free survival (PFS) over THP in first line Her-2 positive MBC as per the press release https://t.co/F0AZ9KUFs7	Positive	1,676
MV Chandrakanth @ChandrakanthMv	DESTINY-Breast09 exploratory analysis (#ASCO2026) T-DXd + pertuzumab responses continued to deepen over time in HER2+ metastatic breast cancer. PRs evolved into CRs. Median time to CR: 8.4 months. Maximum shrinkage: ~11 months. Key messa…	Neutral	1,589
Jason A. Mouabbi MD @JAMouabbi	🚨 #DB09 delivers practice-changing data: T-DXd + pertuzumab shows mPFS ~40 mo (HR 0.56) and ~15% CR rate — with activity regardless of ER or PIK3CAm status. Impressive results. Next step? An induction-maintenance strategy: T-DXd + P for a …	Positive	1,490
Anis Toumeh, MD @AnisToumeh	Long awaited, and expected results by most. Practice will likely change soon. #bcsm	Positive	1,440
Taro Yamanaka @TaroY_oncology	💡Big news for HER2+ MBC! 💡 💥 DESTINY-Breast09 💥 T-DXd + pertuzumab significantly improved PFS vs. THP in 1L setting. 👀 OS data still maturing, but early trends look promising. 📢 Detailed results to follow—future updates will be key. 🔗	Nuanced	1,435
VIRGINIA KAKLAMANI @VKaklamani	Great data of db09 presented by @stolaney1 #ASCO2025 however t of hp was only given for 6 mo whereas tdxd was given to disease progression, still 2 ild deaths, low number of >65yo and only 10% of thp went on to receive tdxd. However 15% cr …	Nuanced	1,394
Guilherme Nader Marta @GuiNaderMarta	DESTINY-Breast09 presented by @stolaney1 at #ASCO25 T-DXd + P improved 1L outcomes in HER2+ mBC vs THP: mPFS (BICR): 40.7 vs 26.9 mo, HR: 0.56 (0.44–0.71), P<0.01 ORR: 85.1% vs 78.6% CR rate: 15.1% vs 8.5% mDOR: 39.2 vs 26.4 mo ⚠️ ILD…	Neutral	1,378
Komal Jhaveri, MD, FACP, FASCO @jhaveri_komal	Another treatment option for our patients with HER2 positive MBC in the 1L setting. TDXD + P was better than THP in DB-09. Awaiting details on magnitude of benefit and safety at upcoming meeting.	Positive	1,325
Megan Kruse @MeganKruseMD	What a thought provoking and stimulating ASCO for the breast cancer community! Still processing it all and looking forward hearing what others think of SERENA-6, DB-09, ASCENT-04 and beyond. #ASCO25 #CleClinicCancer	Positive	960
Elisabetta Bonzano MD, PhD @to_be_elizabeth	📌 Additional analyses of DESTINY-Breast09 in key subgroups of interest Trastuzumab deruxtecan + pertuzumab vs taxane + trastuzumab + pertuzumab for patients with HER2+ advanced/metastatic BC T-DXd + P demonstrated a clinically meaningful …	Positive	854
TwoOncDocs @TwoOncDocs	Important late-breakfast abstract #DESTINYBREAST09 For fellows ➡️ current SOC for HER2+ MBC is THP or DHP (taxane + trastuzumab + pertuzumab ➡️ HER2+ = IHC2+ with +FISH or 3+ ❓# in control arm w/ TDxD at progression ❓sequencing ❓long-ter…	Nuanced	850
gilberto lopes @GlopesMd	DESTINY-Breast09: Trastuzumab Deruxtecan Plus Pertuzumab Sets New First-Line Benchmark in HER2-Positive Metastatic Breast Cancer https://t.co/RnsTcFLlxX @asco #asco25 @GlopesMd	Positive	830
Abi Siva MD @AbiSivaMD	#bcsm 🔥 off the press: DESTINY-Breast09 shows improved PFS with Enhertu and Pertuzumab in the 1st-line metastatic setting! #medtwitter	Positive	825
Nagi El Saghir MD, FASCO, FACP @NagiSaghir	Best strategy would be to give T-Dxd for 1-2 years then maintain patients in remission on Trastuz + Pertuz (wait for the presentation: for observation of time when rate of relapses slows down, and duration of lasting response in patients wh…	Neutral	715
Lorenzo Gerratana @LGerratana	DESTINY-B09 at #ASCO25: ✅ T-DXd + P improved PFS vs THP (40.7 vs 26.9 mo; HR 0.56) 🔭 Benefit consistent across subgroups, incl. PIK3CA mut/wt #MBC ⏱️ ORR 85% with durable responses ⏳ ~16–20% maturity for OS/PFS2 – further follow-up awai…	Neutral	606
Elvina Almuradova @Dr_ElvinaA	Practice-changing data at #ASCO25! T-DXd + pertuzumab in 1L HER2+ MBC: 🔹 Median PFS: 40.7 vs 26.9 mo (HR 0.56, p<0.00001) 🔹 CR rate doubled (15% vs 8%) 🔹 OS trend favored T-DXd (HR 0.84) A new frontline standard? #BreastCancer #DESTINYBreas…	Positive	604
Santhosh Ambika @RenoHemonc	DB-09 -> good responders with HR+ should be deescalated to PATINA regimen..	Neutral	574
Priscila Barreto Coelho, MD @PriscilaBCMD	DESTINY-Breast09 may change 1L tx for HER2+ MBC. Key Qs for #ASCO25: Who benefits most—de novo vs recurrent? ER+ vs ER-? How long do pts stay on T-DXd? What about toxicity & PROs? Are we curing more? Living longer? Let’s see if the hype mee…	Nuanced	470
Eleonora Teplinsky, MD, FASCO @drteplinsky	We talk about SERENA-6, ASCENT-04, DESTINY-Breast09 - what they show, limitations, next steps etc! #ASCO25	Neutral	458
Elisabetta Munzone @elisabettasabet	📢 DESTINY-Breast09 is practice-changing, with 1L T-DXd+P showing 40.7m PFS vs 26.9m. But real-world fit? 31% d/c T-DXd early, only 10% got it 2L. Few pts with prev pertuzumab. Time to rethink duration, QOL, and who needs escalation. #ASCO25…	Positive	196
Laila Agrawal, MD @LailaAgrawalMD	2. First line Tdxd + P - longer exposure to more toxic rx, eliminates non-chemo option (HP after taxane) & most in control arm didn’t get tdxd at progression. Doesn’t prove 1st line Tdxd better than 2nd	Nuanced	128
Corey Speers @cwspeers	🔬 Breast Cancer Breakthroughs 1️⃣ LBA1008 – DESTINY-Breast09 🚨 HER2+ 1st-Line Update: T-DXd + pertuzumab vs THP (taxane + trastuzumab + pertuzumab) in a/mBC. ➡️ Interim results show promising efficacy + safety with T-DXd combos—potential t…	Neutral	116
Dr S. Kumar, MD @doconcology	Dr. Sheheryar Kabraji (@RoswellPark) draws a critical parallel: these findings mirror #DESTINYBreast09 data in HER2+ breast cancer — where T-DXd in earlier lines preserved or improved efficacy. This is precision oncology in action. @SABCS_ …	Positive	30

See full DESTINY-Breast09 conference coverage & trial data →

Trial 2 · NCT04494425

What do oncologists think of the DESTINY-Breast06 trial (ENHERTU®)?

DESTINY-Breast06 — HR+/HER2-low and HER2-ultralow metastatic breast cancer after endocrine therapy

FDA APPROVED · Jan 2025FDA-approved January 27, 2025, for unresectable or metastatic HR-positive, HER2-low or HER2-ultralow breast cancer that has progressed on one or more endocrine therapies.

Physicians are broadly favorable, with real nuance on DESTINY-Breast06: 34% of 41 verified physician voices positive, 12% nuanced (praising the result while flagging a caveat), 47% neutral, 7% critical.

34%

12%

47%

Positive 34% Nuanced 12% Neutral 47% Critical 7%

Denominator: 41 distinct verified physician voices across 104 oncologist posts, 2024-05-20 to 2026-07-12. Sponsor: Daiichi Sankyo (with AstraZeneca)

See full DESTINY-Breast06 conference coverage & trial data →

Primary sources: ClinicalTrials.gov · NCT04494425 · FDA — DESTINY-Breast06 approval (Jan 2025)

FDA approval (Jan 27, 2025): fam-trastuzumab deruxtecan-nxki for unresectable or metastatic HR-positive, HER2-low or HER2-ultralow breast cancer that has progressed on one or more endocrine therapies (based on DESTINY-Breast06, NCT04494425).

Physician voices — verbatim

Representative positive voice

Great discussion by dr Krop @Yale: here the new algorithm for the management of hormone receptor-positive/HER2-negative advanced #BreastCancer after #ASCO24 @OncoAlert

Matteo Lambertini, MD PhD

@matteolambe

Representative nuanced voice

Ian Krop #ASCO24 discussed imp DB06 data. Decisions 1st v 2nd line based on disease extent/aggressiveness of dse. He is sold on ultralow - I am perhaps more conservative but the option for Rx is imp.

Hope Rugo

@hoperugo

Representative critical voice

Good example of the disaster that emerges when you categorize a continuous variable, here HER2 expression

M. Bolton

@5_utr

Full physician voice list (41)

Physician	Comment (verbatim)	Sentiment	Impressions
Yakup Ergün @dr_yakupergun	#ASCO24 DESTINY-Breast06: T-DXd vs TPC in pts with HR+/ HER2-low or HER2-ultralow PFS Low➡️13.2 vs 8.1 mo Ultralow➡️13.2 vs 8.3 mo ORR Low➡️56.5 vs 32.2% Ultralow➡️61.8 vs 26.3% ILD➡️11.3% (0.7% Gr3/4, 0.7% Gr5) vs 0.2% (Gr2) ❗️Atten…	Neutral	20,266
Matteo Lambertini, MD PhD @matteolambe	Great discussion by dr Krop @Yale: here the new algorithm for the management of hormone receptor-positive/HER2-negative advanced #BreastCancer after #ASCO24 @OncoAlert	Positive	14,668
Paolo Tarantino @PTarantinoMD	T-DXd is now approved for the 1L cytotoxic treatment of patients with HR+/HER2-low or #ultralow MBC, based on the results of DB06. Best suited in this 1L setting for pts with visceral and aggressive disease. Next step: unlocking the full sp…	Positive	13,563
Timothée Olivier, MD @Timothee_MD	In today's post of Drug Development Letter, check out why I hope there won’t be a standing ovation after the DESTINY-Breast06 trial presentation at ASCO-2024❗️ subscribe for FREE👇 https://t.co/vadkB2CGPt https://t.co/U3mE9TrrwF	Positive	13,387
Hope Rugo @hoperugo	Ian Krop #ASCO24 discussed imp DB06 data. Decisions 1st v 2nd line based on disease extent/aggressiveness of dse. He is sold on ultralow - I am perhaps more conservative but the option for Rx is imp.	Nuanced	10,429
Bertrand Delsuc @BertrandBio	$AZN #DaiichiSankyo Destiny-Breast06 ENHERTU (T-DXd) demonstrated a mPFS of 13.2mo in HR+ HER2-low and HER2-ultralow metastatic breast cancer after >= 1 lines of endocrine therapy https://t.co/ywU4tMpCfR	Neutral	10,163
Oncology Brothers @OncBrothers	3. #DB06: . DestinyBreast06: Ph III, TDXd vs chemo in endocrine resistant HR+ HER2 low and HER2-ultralow - Improved PFS regardless of time to progression on CDK4/6i or tumor burden - PFS2 better w/ TDXd - In what line will you use this @cu…	Neutral	8,032
Erika Hamilton, MD @ErikaHamilton9	Story short, TDXd was better in all groups. Quick or slow relapsers on DB-06 Regardless of disease burden Among primary or secondary endocrine resistance #SABCS24 @SABCSSanAntonio @OncoAlert	Positive	7,310
Sara Tolaney @stolaney1	Ian Krop beautifully puts DB06 in perspective. Suggests: TDXd should be first-line chemo for pts with symptomatic disease, and short DFI after adj tx Better HER2 testing assays are needed Work needed to evaluate TDXd in HR- HER2ultralo…	Positive	6,580
Yüksel Ürün @DrYukselUrun	The FDA has approved Enhertu as the 1st HER2-directed therapy for HER2-low & HER2-ultralow metastatic breast cancer following progression on endocrine therapy! This marks a paradigm shift for HR-positive patients and expands treatment optio…	Positive	5,533
Toni Choueiri, MD @DrChoueiri	JUST IN: TdX is now ⁦@FDA⁩ approved for patients with HER2-low or HER2-ultralow metastatic breast cancer following 1+ endocrine therapies ⁦@OncoAlert⁩ ⁦@OncBrothers⁩ ⁦@OncLive⁩ ⁦@TargetedOnc⁩ ⁦@AstraZeneca⁩	Neutral	5,296
Elisa Agostinetto @ElisaAgostinett	One of the most awaited LBA at #ASCO24 @curijoey presents results of DestinyBreast06 on T-DXd in HR+, HER2-low and -ultralow BC ➡️ T-DXd⬆️PFS vs. TPC in HER2-low mBC ➡️Results in ultra-low consistent with HER2-low ➡️ILD remains an impor…	Neutral	4,562
𝐂𝐡𝐚𝐧𝐝𝐥𝐞𝐫 𝐏𝐚𝐫𝐤 𝐌𝐃 𝐅𝐀𝐂𝐏 @CParkMD	⭐️ How to sequence 1st line Stage IV ER+ positive breast cancer for patients after Destiny-Breast06 at #ASCO24 . Great to talk to global leader Dr. Giuseppe Curigliano and get his expertise on @oncodaily 👇Full video 👇 https://t.co/kUAVth…	Positive	3,920
Ilana Schlam @IlanaSchlam	🚨🚨🚨LBA: DB06 by @curijoey Outcomes of patients with metastatic HR+ HER2 ultralow (IHC between 0 and 1) treated with TDXd were consistent with the outcomes of those with HER2 low disease PFS 13.2 with TDXd vs 8.3 with chemo OS not mature…	Nuanced	2,975
Francesco Schettini, MD PhD 🇮🇹🇪🇸🇪🇺 @FrancescoSche20	DESTINY-Breast06 results excellently presented by super @curijoey. T-DXd confirmed its efficacy also as 1st line “CT” in HR+/HER2low MBC, as well as in UltraLow. Though it is more toxic than standard CT (ILD!) and is likely that standard CT…	Nuanced	2,589
Gaia Griguolo @GaiaGriguolo	Subgroup analysis of Destiny-Breast06 confirms benefit from T-DXd irrespective of time to progression on ET+CdK4/6i and disease burden #SABCS24 @dradityabardia @OncoAlert	Positive	2,561
Taha Koray Sahin @tkoraysahin	☀️Day 3 at #ASCO24 kicked off with an amazing presentation by @curijoey on the promising T-DXd results for HER2-low and HER2-ultralow mBC. This could be a potential game-changer! #DESTINYbreast06 @OncoAlert @DenizCanGuven1 @aksoysercan @i…	Positive	1,731
Arya Roy @royaryam	Updates on HR+HER2- #breastcancer by @DrSGraff at the Upstate NY Cancer Symposium! Lot of exciting data: utilization of AMH in early stage BC, DESTINYBreast06 in HER2low & ultralow BC! @sdent_duke @gandhi_shipra @OncBrothers @BrownUniversit…	Positive	1,548
Punit @punitbansal14	Enhertu \| HER2 Clinical Trial Design \| ADC Therapy 📸1: Enhertu - HER2 - Approved in China, Europe & Japan First HER2 - Directed Therapy for Patients - DESTINY 06 DESTINY-Breast06 was designed to move ENHERTU® earlier in the treatment para…	Neutral	1,510
Marta Perachino @MartaPerachino	#ASCO24 Early birds 🐣 for DESTINY-Breast06 results presentation Key points: 📍clinical and statistical benefit of TDXd in pts HR+HER2low pts in PD to CDK4/6 📍consistent data in ultra-low population 📍OS data immature 📍ILD remains an AE to be…	Nuanced	1,338
M. Bolton @5_utr	Good example of the disaster that emerges when you categorize a continuous variable, here HER2 expression	Negative	1,226
Oriol Mirallas MD @DrMirallas	#ASCO24 💥 LBA: Destiny-B06💥 👉🏼HR+ mBC HER2low/ULTRAlow🔬 =>1/2L of ET+/-TT 💉 T-DXd 5.4mg/kg Q3W vs CT choice ORR 57.3% vs 31% PFS 13.2 vs 8.1m HR 0.62/.63 in HERlow+ULTRAlow OS at 12m 87.6 vs 81.7% NS, 40% maturity ☣️=>G3 40.6 vs 31.4%❗ ☠️3 …	Neutral	1,208
Dr Amol Akhade @SuyogCancer	Updated analysis of destiny breast 06 . Full abstract below. @ASCO #ASCO25 https://t.co/vfmdeVmkgk	Neutral	1,172
𝐋𝐮𝐢𝐳 𝐆𝐮𝐬𝐭𝐚𝐯𝐨 𝐓𝐨𝐫𝐫𝐞𝐬, MD @lgtorres74	The FDA has approved Enhertu as the 1st HER2-directed therapy for HER2-low & HER2-ultralow metastatic breast cancer following progression on endocrine therapy! This marks a paradigm shift for HR-positive patients and expands treatment optio…	Positive	917
Elisabetta Bonzano MD, PhD @to_be_elizabeth	📌Enhertu approved in the US as first HER2-directed therapy for patients with HER2-low or HER2-ultralow metastatic breast cancer following disease progression after one or more endocrine therapies ⁦@OncoAlert⁩ #OncoAlertAF	Neutral	883
Rani Bansal, MD @DrRaniBansal	Great review by @oreganruth on post-CDK4/6i trials - ❓is there benefit for switching from ribo to abema in 2nd line (only 1/3 pts received ribo first line in postmonarch) ⭐️current treatment pathway for ER+HER2- MBC… ❓DESTINY 06 results m…	Positive	875
Bishal Gyawali, MD, PhD, FASCO @oncology_bg	I see that Destiny Breast 06 is making news today after the FDA approval. These were my thoughts about that trial immediately after it was presented at #ESMO24. Check it out. Starts at 5:54. https://t.co/aDN88aLdIY @ecancer	Negative	856
Chiara Corti @CCortiMD	DESTINY-Breast06 results presented by @curijoey. T-DXd showed efficacy also as 1st line cytotoxic agent in HR+ HER2low (n=713) and UltraLow (n=153) mBC. 🚨11% ILD (3 g5). #MedscapeFellow @oncodaily	Neutral	626
Naoto T Ueno, MD, PhD @teamoncology	Enhertu is approved for low or ultralow HER2 after one line of endocrine therapy. I understand the data. Is it truly a bad idea to give T-DXd after Xeloda for low-volume or slow-growing diseases? Can you not give T-DXd after Xeloda?	Neutral	582
Vivek Subbiah, MD @VivekSubbiah	🚨⭐️ FDA approval alert 👉🏼ENHERTU® Approved in the U.S. as First HER2 Directed Therapy for Patients with HER2 Low or HER2 Ultralow Metastatic Breast Cancer Following Disease Progression After One or More Endocrine Therapies \| Business Wire	Neutral	469
Amalya Sargsyan @amalsargsyan	#BGICC2025 kicked off with 5000 attendees in Cairo, Egypt! Prof. @curijoey set the stage with an inspiring session on DESTINY-Breast06, highlighting the potential of T-DXd in HER2-low/ultralow HR+ mBC. @oncodaily is here—stay tuned for liv…	Positive	387
ChiaraMolinelli @ChiaraMolinelli	#ASCO24 DESTINY-Breast06 results presented today. T-DXd significantly improved PFS in HR+/HER2 low and ultra low mBC. AEs: well-known GI toxicity, ILD must be always taken into consideration. A great presentation by @curijoey and an extra…	Positive	382
Dr. Ron DePinho @RonDePinho	FDA Expands Enhertu Approval to HER2-Ultralow Breast Cancer	Neutral	363
Abi Siva MD @AbiSivaMD	Enhertu approved in the US as first HER2-directed therapy for patients with HER2-low or HER2-ultralow metastatic breast cancer following disease progression after one or more endocrine therapies. #bcsm #medtwitter ⁦@ASCO⁩ ⁦@OncoAlert⁩	Neutral	354
Willem Lybaert @WLybaert	Most recent treatment scheme to use in our clinic#ASCO 2024 after Destiny-Breast06💥💥💥	Neutral	223
Arturo LoAIza-Bonilla, MD MSEd @DrBonillaOnc	FDA Approves Trastuzumab Deruxtecan for Pretreated HER2-Low and -Ultralow Metastatic Breast Cancer https://t.co/NUqxzVJdny via @onclive	Neutral	197
Hossam Abdulkhalek MD MSc FRCP @hosamrgb	New concept of HER2 Ultralow Destiny Breast06 #ASCO24	Neutral	178
Deborah Doroshow @DDoroshow	This is great news. But we shouldn't have to post news about an FDA approval from a drug company press release. #medtwitter	Nuanced	165
Dr Sarah Sammons @drsarahsam	Agree we need more data here and an actual biomarker.	Negative	143
carolyn johnston @DrCJohn	Half a story, unless you add that Destiny-Breast06 study was sponsored by AZ, and also list the price of the drug with an indication of what that means for other budgets.	Neutral	96
Tess O'Meara, MD, MHS @tess_omeara	In subgroup analyses of #DESTINYBreast06 of T-DXd in HER2 low and ultralow HR+ mBC, @dradityabardia reports improved ORR and PFS of T-DXd compared to standard chemo regardless of time to progression on 1L endocrine-based therapy or met dise…	Neutral	93

See full DESTINY-Breast06 conference coverage & trial data →

Trial 3 · NCT03529110

What do oncologists think of the DESTINY-Breast03 trial (ENHERTU®)?

DESTINY-Breast03 — 2L+ HER2-positive metastatic breast cancer (T-DXd vs T-DM1)

FDA APPROVED · May 2022FDA-approved May 4, 2022, for unresectable or metastatic HER2-positive breast cancer after a prior anti-HER2-based regimen (second-line and beyond).

Physicians are genuinely mixed on DESTINY-Breast03: 0% of 3 verified physician voices positive, 33% nuanced (praising the result while flagging a caveat), 67% neutral, 0% critical.

33%

67%

Positive 0% Nuanced 33% Neutral 67% Critical 0%

Denominator: 3 distinct verified physician voices across 6 oncologist posts, 2024-05-25 to 2025-10-19. Sponsor: Daiichi Sankyo (with AstraZeneca)

See full DESTINY-Breast03 conference coverage & trial data →

Primary sources: ClinicalTrials.gov · NCT03529110

Physician voices — verbatim

Representative nuanced voice

Maybe can you explain to a young doctor huge differences in pfs but not so much in os?

Gianmarco Ricagno, MD

@giammi107

Full physician voice list (3)

Physician	Comment (verbatim)	Sentiment	Impressions
Yakup Ergün @dr_yakupergun	#ASCO24 T-DXd vs T-DM in patients with HER2+ mBC: Updated survival results of DESTINY-Breast03 PFS➡️29.0 vs 7.2 mo OS➡️52.6 vs 42.7 mo ORR➡️79% vs 37% ILD➡️16.7% vs 3.4% (all <G4) https://t.co/1dFve8REAf	Neutral	4,389
Antonio Giordano, MD PhD @antgiorda	in 2L HER2+ metastatic breast cancer, in 10 years, from 2012 to 2022, we have reduced risk of progression and death by !!80%!! - Lapatinib + cape 6.4 months - TDM1 9.6 months - TDXd 29.1 months #ESMO25 Dr. Rupert Bartsch	Neutral	2,268
Gianmarco Ricagno, MD @giammi107	Maybe can you explain to a young doctor huge differences in pfs but not so much in os?	Nuanced	258

See full DESTINY-Breast03 conference coverage & trial data →

Trial 4 · NCT05113251

What do oncologists think of the DESTINY-Breast11 trial (ENHERTU®)?

DESTINY-Breast11 — Neoadjuvant HER2-positive Stage II/III early breast cancer

FDA APPROVED · May 2026FDA-approved May 15, 2026, as neoadjuvant treatment of HER2-positive (IHC 3+ or ISH+) Stage II or III breast cancer, followed by a taxane, trastuzumab, and pertuzumab (THP).

Physicians are broadly favorable, with real nuance on DESTINY-Breast11: 39% of 36 verified physician voices positive, 17% nuanced (praising the result while flagging a caveat), 33% neutral, 11% critical.

39%

17%

33%

11%

Positive 39% Nuanced 17% Neutral 33% Critical 11%

Denominator: 36 distinct verified physician voices across 82 oncologist posts, 2025-05-07 to 2026-06-01. Sponsor: Daiichi Sankyo (with AstraZeneca)

See full DESTINY-Breast11 conference coverage & trial data →

Primary sources: ClinicalTrials.gov · NCT05113251 · FDA — early-breast-cancer approvals (May 2026)

FDA approval (May 15, 2026): fam-trastuzumab deruxtecan-nxki as neoadjuvant treatment of HER2-positive (IHC 3+ or ISH+) Stage II or III breast cancer, followed by THP — one of two early-breast-cancer indications approved that day (based on DESTINY-Breast11, NCT05113251).

Physician voices — verbatim

Representative positive voice

High expectations from #CompassHER2pCR and #DESTINYBreast11 to expand our anthracycline-free treatment options for HER2+ breast cancer. For a future where most patients can be cured with less alopecia, fatigue, neutropenia, cardiotoxicity and secondary leukemias.

Paolo Tarantino

@PTarantinoMD

Representative nuanced voice

Another positive trial in #bcsm, TDXd followed by THP beats ddAC-THP in neoadjuvant HER-2+ early breast cancer. We've seen a lot of positive TDXd results, but this is the FIRST 🥇in the early stage setting! @OncBrothers @OncoAlert

Erika Hamilton, MD

@ErikaHamilton9

Representative critical voice

Tdxd alone was not effective as NACT . I am surprised. Are u ? #destinybreast11 @dr_yakupergun @ErikaHamilton9 @myESMO

Dr Amol Akhade

@SuyogCancer

Full physician voice list (36)

Physician	Comment (verbatim)	Sentiment	Impressions
Santhosh Ambika @RenoHemonc	Go with Tolaney approach to spare unnecessary Rx.	Neutral	12,482
Erika Hamilton, MD @ErikaHamilton9	Another positive trial in #bcsm, TDXd followed by THP beats ddAC-THP in neoadjuvant HER-2+ early breast cancer. We've seen a lot of positive TDXd results, but this is the FIRST 🥇in the early stage setting! @OncBrothers @OncoAlert	Nuanced	8,229
Abi Siva MD @AbiSivaMD	Noticed in the latest @NCCN update: post-neoadjuvant T-DXd made the list, but neoadjuvant T-DXd + THP didn’t. Curious whether this signals preference for DB-05 vs DB-11, or simply where the evidence is easiest to implement. @PTarantinoMD @J…	Nuanced	7,294
Dr Amol Akhade @SuyogCancer	Tdxd alone was not effective as NACT . I am surprised. Are u ? #destinybreast11 @dr_yakupergun @ErikaHamilton9 @myESMO	Negative	7,025
Paolo Tarantino @PTarantinoMD	High expectations from #CompassHER2pCR and #DESTINYBreast11 to expand our anthracycline-free treatment options for HER2+ breast cancer. For a future where most patients can be cured with less alopecia, fatigue, neutropenia, cardiotoxicity a…	Positive	6,574
Yakup Ergün @dr_yakupergun	📣It was announced that the DESTINY-Breast11 study yielded positive results in terms of pCR. The comparison arms referenced in the pCR announcement are: T-DXd ➡️ THP vs ddAC ➡️ THP https://t.co/3MhRzIwG1i	Positive	6,572
Kazuki Nozawa, MD @kazuki_nozawa	DESTINY-Breast11試験術前化学療法としてT-DXd→THPはpCRの改善)Δ11.2%と良好ないEFS結果を報告しました。 non-pCR対する術後T-DXdのDESTINY-Breast05試験もポジティブで、どこでT-DXdを使うべきかの論争が始まりました。 #ESMO25 https://t.co/MvzN2nbDdy	Neutral	6,442
Stephanie Graff, MD, FACP, FASCO @DrSGraff	How are we feeling on Sunday morning RE: Destiny Breast 11 (neoadj) and DB-05 (residual disease)? What are we doing in the overlapping population? (Don’t vote just to see; that’s what the bookmark tab is for!) #ESMO25	Neutral	6,394
Hope Rugo @hoperugo	#SABCS2025 @curijoey and Sybille Loibl present safety data from DB11 and DB05. Most encouraging is the lack of an increase in ILD/pneumonitis when TDXd is given through adjuvant RT. Very careful monitoring and management will be critical in…	Positive	5,704
Dr Rishabh Jain @DrRishabhOnco	#ESMOBreast26 DESTINY-Breast11: T-DXd→THP improved favorable RCB-0/I rates across all major HER2+ EBC subgroups 👀 🔹 HR+: 78.0% vs 64.7% 🔹 HR-: 90.4% vs 81.2% 🔹 Node-negative: 80.8% vs 68.6% 🔹 Node-positive: 81.5% vs 69.8% 📌 Benefit exte…	Positive	4,549
MV Chandrakanth @ChandrakanthMv	DESTINY-Breast11 (DB-11) – RCB Analysis T-DXd-THP significantly improves Residual Cancer Burden compared to standard ddAC-THP in high-risk HER2+ early breast cancer. Key Highlights: • RCB-0+I rate: 81.3% vs 69.1% (+12.2%) • Consistent benef…	Neutral	4,082
Gaia Griguolo @GaiaGriguolo	DESTINY-Breast11 pCR ↑ 11% ✅ But leaves open questions: -How would THP-TDXd compare with anthra-free regimens (TCbHP)? - if RD, would post-neoadj T-DM1 or TDXd (DB-05) be active? - are low ILD rates due to short duration or to stric…	Nuanced	3,307
Yüksel Ürün @DrYukselUrun	DESTINY-Breast11: Neoadjuvant T-DXd + THP improves pCR by 11.2% vs ddAC-THP in HER2+ early breast cancer! A step closer to redefining HER2-positive neoadjuvant therapy. #ESMO25 #BreastCancer @TeresaSAmaral @E_de_Azambuja @JyotiBajpai01 …	Positive	3,262
Matteo Lambertini, MD PhD @matteolambe	Just presented at the #ESMO25 presidential session by @Prof_Nadia_H the first data from #DESTINYbreast11 trial investigating neoadjuvant #TDXd to replace anthra-based chemotherapy in patients with early #HER2-positive #BreastCancer @OncoA…	Positive	3,146
Toni Choueiri, MD @DrChoueiri	Practice-shaping presidential caliber from @Prof_Nadia_H! DESTINY-Breast11: neoadjuvant T-DXd→THP tops ddAC-THP on pCR 67.3% vs 56.3% (Δ11.2%, p=0.003). Early positive trend in EFS. #ESMO25 #BreastCancer @myESMO @Annals_Oncology @DanaFarber	Positive	3,020
Oncology Brothers @OncBrothers	5. #DESTINYBreast11: PhIII, NeoAdj TDXd +/- THP vs. ddAC-THP in high risk Her2+ locally advanced early breast cancer: - QoL and 20 symptomatic AEs better with TDXd-THP or TDXd alone vs. ddAC-THP 6/7 https://t.co/UnDrOIKL4V	Neutral	2,035
Luca Arecco, MD @Lucarecco	Over half voters (53%) would opt for TCHP → T-DXd as preferred sequencing in HER2+ eBC setting. The key challenge is now finding the optimal sequencing and patient selection while awaiting further updates from DB-11 and DB-05. @OncoAlert	Negative	1,588
Elisabetta Bonzano MD, PhD @to_be_elizabeth	📌Enhertu followed by THP before surgery showed statistically significant and clinically meaningful improvement in pathologic complete response in patients with high-risk HER2-positive early-stage breast cancer in DESTINY-Breast11 PhaseIII t…	Positive	1,588
Aya Mohamed \| MSc, MD 🎗 @dr_oncologista	DESTINY-Breast11: T-DXd–Based Neoadjuvant Therapy Outperforms Anthracycline-Containing Regimens in High-Risk HER2+ EBC, Delivering Higher pCR and RCB 0/1 Rates and Supporting a Shift Toward an Anthracycline-Free Standard @OncoAlert #ESMO…	Neutral	1,162
Icro Meattini @Icro_Meattini	DESTINY-Breast11 support T-DXd-THP as a more effective and less toxic neoadjuvant treatment vs ddAC-THP #ESMO25 #OncoAlert @OncoAlert #BreastCancer	Positive	1,123
Kristina Jankovic, MD @JankovicK	First results from #DESTINYBreast11 show that neoadjuvant #TDXd-THP significantly improves pCR 🆚 anthracycline-based ddAC-THP in early #HER2positive #BreastCancer 🎀 💡 Benefit seen in both HR+ and HR– subgroups 📈 Early positive trend in EFS…	Positive	1,013
César A. Rodríguez 🩺 🐾 @1969carodriguez	News from #ESMO2025 7️⃣ Great results from DestinyBreast11 Trial, but many questions open for discussion, in particular, lack of mature data of EFS, variability of postSurgery treatment, and how to combine this approach with DestinyBreast05…	Nuanced	867
Hakan Önder @onder_haka2124	As long as physicians receive direct or indirect payments from industry for clinical trial participation, true scientific equipoise is impossible. What did you expect? In such a system, research ethics can’t flourish decisions inevitably dr…	Negative	625
Prof. Dr. Ahmet Dirican @dr_dirican	FDA has granted two new approvals for ENHERTU (trastuzumab deruxtecan) in HER2-positive early breast cancer. 🔹 Neoadjuvant setting (DESTINY-Breast11) 🔹 Adjuvant treatment for residual disease (DESTINY-Breast05) Some remarkable findings: …	Positive	453
Elvina Almuradova @Dr_ElvinaA	Presidential Symposium 1 @ESMO_Open #DestinyBreast11 neoadjuvant HER2+ eBC T-DXd-THP vs ddAC-THP ✅ pCR: 67.3% vs 56.3% (Δ 11.2%, P=0.003) ↗ Benefit in both HR+ (61.4% vs 52.3%) & HR− (83.1% vs 67.1%) Early favorable EFS trend Grade ≥3 AE…	Neutral	404
M. Bolton @5_utr	Incredible spin: “Showed inferior but robust” 😵‍💫	Nuanced	400
Dr Sarah Sammons @drsarahsam	Residual high risk only	Neutral	282
Mustafa Özdoğan, MD @ozdogan_md	Two positive trials — two crucial questions: Who needs T-DM1 after neoadjuvant T-DXd, and what is the best regimen before maintenance T-DXd?	Positive	267
Tuğba Başoğlu, MD @tugbawitter	🚨 #ESMO25 BREAKING: DESTINY-Breast11 shows T-DXd-THP achieves highest ever pCR (67.3%) in high-risk HER2+ eBC 💥 ➕ Statistically significant improvement vs ddAC-THP (Δ11.2%, p=0.003) 📉 EFS trend favors T-DXd-THP (HR: 0.56) A potential new ne…	Positive	260
Elisa Agostinetto @ElisaAgostinett	Hi Luca, nice poll! I would recommend post-neoajuvant T-DXd only in the DB-05 criteria (ie, residual disease in the lymphnodes at surgery or inoperable disease at diagnosis) and not for all cases of residual disease! T-DM1 is still SoC for …	Neutral	253
Raffaele Colombo @raffcolo	Median onset is ~5-6 months. So 4 cycles is below the median	Neutral	251
Nurullah İlhan,MD @drnurullahilhan	#ASCO Highlights session presentation of DESTINY-Breast11 by @DrWGradishar. DESTINY-Breast11 – Phase 3, global, multicenter, open-label, randomized trial in high-risk HER2-positive early breast cancer (neoadjuvant setting). Primary endpoint…	Positive	130
Anis Toumeh, MD @AnisToumeh	Not sure what the implications are here, especially if we end up learning that indeed, THP is enough for most patients. We need to see the data.	Negative	104
Uğur özkerim @UOzkerim	It seems @stolaney1 “response-guided” approach might be the most reasonable direction after all 👀 HER2 eBC management keeps evolving — precision and flexibility will be key. #ESMO25 @OncoAlert @OncoReporte @MedwatchKate @PTarantinoMD @brun…	Neutral	93
Bijoy Telivala @BijoyTelivala	Suspect yes Suspect T DXd followed by THP will the chosen regimen based on Destiny - Breast 11	Neutral	43
Ethan Ludmir MD @ebludmir	I’m using that in my day-to-day life from now on. My kid’s art: inferior but robust. @DrEmmaHolliday	Nuanced	32

See full DESTINY-Breast11 conference coverage & trial data →

Trial 5 · NCT04622319

What do oncologists think of the DESTINY-Breast05 trial (ENHERTU®)?

DESTINY-Breast05 — Adjuvant HER2-positive early breast cancer with high-risk residual disease

FDA APPROVED · May 2026FDA-approved May 15, 2026, as adjuvant treatment of HER2-positive early breast cancer with residual invasive disease following neoadjuvant trastuzumab- (with or without pertuzumab) and taxane-based treatment.

Physicians are broadly favorable, with real nuance on DESTINY-Breast05: 23% of 26 verified physician voices positive, 8% nuanced (praising the result while flagging a caveat), 65% neutral, 4% critical.

23%

65%

Positive 23% Nuanced 8% Neutral 65% Critical 4%

Denominator: 26 distinct verified physician voices across 60 oncologist posts, 2025-10-18 to 2026-06-01. Sponsor: Daiichi Sankyo (with AstraZeneca)

See full DESTINY-Breast05 conference coverage & trial data →

Primary sources: ClinicalTrials.gov · NCT04622319 · FDA — early-breast-cancer approvals (May 2026)

FDA approval (May 15, 2026): fam-trastuzumab deruxtecan-nxki as adjuvant treatment of HER2-positive early breast cancer with residual invasive disease after neoadjuvant trastuzumab- and taxane-based therapy — one of two early-breast-cancer indications approved that day (based on DESTINY-Breast05, NCT04622319).

Physician voices — verbatim

Representative positive voice

#SABCS2025 @curijoey and Sybille Loibl present safety data from DB11 and DB05. Most encouraging is the lack of an increase in ILD/pneumonitis when TDXd is given through adjuvant RT. Very careful monitoring and management will be critical in this setting @OncoAlert

Hope Rugo

@hoperugo

Representative nuanced voice

Noticed in the latest @NCCN update: post-neoadjuvant T-DXd made the list, but neoadjuvant T-DXd + THP didn’t. Curious whether this signals preference for DB-05 vs DB-11, or simply where the evidence is easiest to implement. @PTarantinoMD @JAMouabbi @drsarahsam @OncBrothers

Abi Siva MD

@AbiSivaMD

Representative critical voice

Over half voters (53%) would opt for TCHP → T-DXd as preferred sequencing in HER2+ eBC setting. The key challenge is now finding the optimal sequencing and patient selection while awaiting further updates from DB-11 and DB-05. @OncoAlert

Luca Arecco, MD

@Lucarecco

Full physician voice list (26)

Physician	Comment (verbatim)	Sentiment	Impressions
Sara Tolaney @stolaney1	DESTINY-Breast05 ILD/radiation pneumonitis ILD higher in pts from Japan and in pts with moderate/renal impairment @OncoAlert #ASCO26	Neutral	17,165
Santhosh Ambika @RenoHemonc	Go with Tolaney approach to spare unnecessary Rx.	Neutral	12,482
Paolo Tarantino @PTarantinoMD	Adjuvant T-DXd is approved for pts with HER2+ BC and high-risk RD by DB05 criteria. What about pts with lower risk RD? We looked at ~10.000 pts in Flatiron, finding that 52% have low-risk RD, with 3yr DRFS 94%, suggesting that T-DM1 remains…	Neutral	10,624
Yakup Ergün @dr_yakupergun	#ASCO26 DESTINY-Breast05 ILD analysis ILD was more frequent with T-DXd. Interesting signal: ILD was more common in Japan. Genetic susceptibility, imaging/diagnostic threshold, reporting practice, and RT techniques may all contribute. RT…	Neutral	7,884
Abi Siva MD @AbiSivaMD	Noticed in the latest @NCCN update: post-neoadjuvant T-DXd made the list, but neoadjuvant T-DXd + THP didn’t. Curious whether this signals preference for DB-05 vs DB-11, or simply where the evidence is easiest to implement. @PTarantinoMD @J…	Nuanced	7,294
Kazuki Nozawa, MD @kazuki_nozawa	DESTINY-Breast11試験術前化学療法としてT-DXd→THPはpCRの改善)Δ11.2%と良好ないEFS結果を報告しました。 non-pCR対する術後T-DXdのDESTINY-Breast05試験もポジティブで、どこでT-DXdを使うべきかの論争が始まりました。 #ESMO25 https://t.co/MvzN2nbDdy	Neutral	6,442
Stephanie Graff, MD, FACP, FASCO @DrSGraff	How are we feeling on Sunday morning RE: Destiny Breast 11 (neoadj) and DB-05 (residual disease)? What are we doing in the overlapping population? (Don’t vote just to see; that’s what the bookmark tab is for!) #ESMO25	Neutral	6,394
Hope Rugo @hoperugo	#SABCS2025 @curijoey and Sybille Loibl present safety data from DB11 and DB05. Most encouraging is the lack of an increase in ILD/pneumonitis when TDXd is given through adjuvant RT. Very careful monitoring and management will be critical in…	Positive	5,704
Dr Rishabh Jain @DrRishabhOnco	🚨 FDA expands the role of Enhertu in curative-intent HER2+ early breast cancer. AstraZeneca + Daiichi Sankyo’s trastuzumab deruxtecan is now approved in the US in BOTH: 🔹 Neoadjuvant setting (DESTINY-Breast11) 🔹 Adjuvant residual disease s…	Neutral	4,378
Sherene Loi, MD @LoiSher	DB05 #esmo25 impressive efficacy for post op node + or inoperable at baseline -balanced with ~10%ILD but 👏less CNS 🧠recurrences 🙌 Bravo to those >70% patients putting up with all that nausea!! @myESMO #esmoambassadors @OncoAlert	Nuanced	3,888
Yüksel Ürün @DrYukselUrun	Excellent discussion as always by @stolaney1 shedding new light on HER2+ treatment direction.@myESMO #ESMO25	Neutral	3,816
MV Chandrakanth @ChandrakanthMv	T-DM1 or T-DXd after neoadjuvant therapy? Residual HER2+ disease after NAC does not automatically mean adjuvant T-DXd. 🔹 KATHERINE → any residual invasive disease qualified for T-DM1 🔹 DESTINY-Breast05 → T-DXd studied in higher-risk resid…	Neutral	2,531
Erika Hamilton, MD, FASCO @ErikaHamilton9	cautions to follow the trial data for #DB05 Should not use T-DXd in ALL HER-2 + #bcsm with residual disease- only those that met trial entry..really unresectable large size or node positive #ESMO25 #ESMOAmbassadors	Positive	2,214
Elisabetta Bonzano MD, PhD @to_be_elizabeth	📌Excellent discussion by @stolaney1 ✨ at Presidential Symposium I #ESMO25 “Reshaping Destiny: trasforming outcomes in high-risk HER2+ BC” DESTINY-Breast05 @OncoAlert #OncoAlertAF @DFCI_BreastOnc	Positive	1,974
Oncology Brothers @OncBrothers	2. #DESTINYBreast05: PhIII, TDXd vs. TDM1 in high risk (inoperable or LN+) residual disease after NeoAdj chemo for Her2+ Breast Cancer: - ⬆️DFS & iDFS w/ TDXd (HR: 0.47 in both end points). - ILD: 9.6% vs. 1.6% - New SoC/option for that v…	Neutral	1,919
Luca Arecco, MD @Lucarecco	Over half voters (53%) would opt for TCHP → T-DXd as preferred sequencing in HER2+ eBC setting. The key challenge is now finding the optimal sequencing and patient selection while awaiting further updates from DB-11 and DB-05. @OncoAlert	Negative	1,588
Dr Rupam Manna MD @DrRupamOncology	🚨 T-DXd vs T-DM1 after neoadjuvant therapy in HER2+ early breast cancer — how do we choose between DESTINY-Breast05 and KATHERINE? KATHERINE made T-DM1 the standard for residual disease. DESTINY-Breast05 now shows T-DXd delivers 92.4% vs 83…	Neutral	1,224
César A. Rodríguez 🩺 🐾 @1969carodriguez	News from #ESMO2025 7️⃣ Ladies and Gentlemen… with you the first analysis of DestinyBreast05 Trial @myESMO	Neutral	1,011
Aya Mohamed \| MSc, MD 🎗 @Dr_Oncologista	The @NEJM DESTINY-Breast05 trial is practice-changing: T-DXd cut recurrence/death risk by ~53% vs T-DM1 in high-risk HER2+ early breast cancer with residual disease after neoadjuvant therapy. @OncoAlert #SABCS25 #BreastCancer #bcsm htt…	Positive	976
Toni Choueiri, MD @DrChoueiri	JUST IN: @FDA approves Neoadjuvant Trastuzumab deruxtecan (TdXD) for Her-2 + breast cancer and post residual disease , based upon Destiny breast 011/05 trials. https://t.co/fGjcZZ9Ay9	Neutral	453
Prof. Dr. Ahmet Dirican @dr_dirican	FDA has granted two new approvals for ENHERTU (trastuzumab deruxtecan) in HER2-positive early breast cancer. 🔹 Neoadjuvant setting (DESTINY-Breast11) 🔹 Adjuvant treatment for residual disease (DESTINY-Breast05) Some remarkable findings: …	Positive	453
Dr Sarah Sammons @drsarahsam	Residual high risk only	Neutral	282
Mustafa Özdoğan, MD @ozdogan_md	Two positive trials — two crucial questions: Who needs T-DM1 after neoadjuvant T-DXd, and what is the best regimen before maintenance T-DXd?	Positive	267
Elisa Agostinetto @ElisaAgostinett	Hi Luca, nice poll! I would recommend post-neoajuvant T-DXd only in the DB-05 criteria (ie, residual disease in the lymphnodes at surgery or inoperable disease at diagnosis) and not for all cases of residual disease! T-DM1 is still SoC for …	Neutral	253
Dr Amol Akhade @SuyogCancer	Trastuzumab deruxtecan gets @US_FDA approval for NACT and for post NACT residual disease , based upon Destiny breast 011 and 05 trials . Expected approval especially for DB 05 setting . @stolaney1 @ErikaHamilton9 @dr_yakupergun @PTarantinoM…	Neutral	144
tatsunori_shimoi 下井辰徳 @shimoi_oncology	#ASCO26 DB05 術前抗がん剤治療でnon pCRでのT-DXd 日本人は強いT-DXdによるILDのリスクで、14.9%だった。T-DM1でも6.7%と高め。 10%程度の全体または非日本人のT-DXdのILD頻度からはだいぶ高い。腎機能低下も一つのリスク。	Neutral	54

See full DESTINY-Breast05 conference coverage & trial data →

Trial 6 · NCT04704934

What do oncologists think of the DESTINY-Gastric04 trial (ENHERTU®)?

DESTINY-Gastric04 — 2L HER2-positive gastric/GEJ adenocarcinoma (T-DXd vs ramucirumab + paclitaxel)

FDA APPROVED · gastric since Jan 2021The HER2-positive gastric/GEJ adenocarcinoma indication has been FDA-approved since January 15, 2021 (originally via DESTINY-Gastric01). DESTINY-Gastric04 is the confirmatory Phase III trial — a second-line overall-survival benefit versus ramucirumab plus paclitaxel — confirming the existing indication rather than adding a new one.

Physicians are broadly favorable, with real nuance on DESTINY-Gastric04: 50% of 26 verified physician voices positive, 8% nuanced (praising the result while flagging a caveat), 42% neutral, 0% critical.

50%

42%

Positive 50% Nuanced 8% Neutral 42% Critical 0%

Denominator: 26 distinct verified physician voices across 41 oncologist posts, 2023-06-30 to 2025-06-22. Sponsor: Daiichi Sankyo (with AstraZeneca)

See full DESTINY-Gastric04 conference coverage & trial data →

Primary sources: ClinicalTrials.gov · NCT04704934 · FDA — HER2+ gastric approval (Jan 2021)

FDA approval (Jan 15, 2021): fam-trastuzumab deruxtecan-nxki for HER2-positive locally advanced or metastatic gastric or gastroesophageal junction adenocarcinoma after a prior trastuzumab-based regimen (indication basis: DESTINY-Gastric01). DESTINY-Gastric04 (NCT04704934) is the confirmatory Phase III second-line trial.

Physician voices — verbatim

Representative positive voice

DESTINY-Gastric04 demonstrated significantly prolonged OS with T-DXd vs. PTX+RAM in HER2+ gastric cancer. A major advancement for patients! Congratulations to all involved! @OncoAlert @oncodaily @DaiichiSankyoUS @AstraZeneca

Kohei shitara

@KoheiShitara

Representative nuanced voice

🚨 New 2nd-line standard in HER2+ gastric cancer? 🔥 The DESTINY-Gastric04 trial shows T-DXd significantly improves OS (14.7 vs 11.4 mo) and ORR (44.3% vs %29.1) vs RAM+PTX. 📉 ILD risk remains—but mostly low-grade. 👨‍⚕️ Presented by @KoheiShitara 📄 Simultaneously published

Mustafa Özdoğan, MD

@ozdogan_md

Full physician voice list (26)

Physician	Comment (verbatim)	Sentiment	Impressions
Kohei shitara @KoheiShitara	DESTINY-Gastric04 demonstrated significantly prolonged OS with T-DXd vs. PTX+RAM in HER2+ gastric cancer. A major advancement for patients! Congratulations to all involved! @OncoAlert @oncodaily @DaiichiSankyoUS @AstraZeneca	Positive	10,249
Nicholas Hornstein @GIMedOnc	#ASCO25 DESTINY-Gastric04 sets a new 2L standard for HER2+ gastric/GEJ cancer. T-DXd vs Ramucirumab/Paclitaxel in post-trastuzumab GEJ/gastric AC (N=494): 🧬 OS: 14.7 vs 11.4 mo (HR 0.70, p=0.004) 📉 PFS: 6.7 vs 5.6 mo 🎯 ORR: 44% vs 29% S…	Neutral	8,818
Arndt Vogel @ArndtVogel	ENHERTU® Demonstrated Statistically Significant and Clinically Meaningful Improvement in Overall Survival in Patients with HER2 Positive Metastatic Gastric Cancer at Interim Analysis of DESTINY- Gastric04 Phase 3 Trial 👉ENHERTU more effecti…	Positive	4,727
Yakup Ergün @dr_yakupergun	Great news!! T-DXd has demonstrated an OS benefit in second-line treatment of HER2-positive metastatic gastric cancer, as announced in the DESTINY-Gastric04 trial. Due to its efficacy, the study has been unblinded https://t.co/N8LSIynm5i	Positive	4,668
Vivek Subbiah, MD @VivekSubbiah	6/ Trastuzumab Deruxtecan or Ramucirumab plus Paclitaxel in Gastric Cancer #ASCO25 @ASCO @NEJM	Neutral	4,410
Dr Amol Akhade @SuyogCancer	Expected results. Trastuzumab deruxtecan shows OS benifit in second line Advanced stomach cancer against paclitaxel plus ramucirumab in her2 3 plus and 2 plus fish positive patients . Press release It will be intresting to see magnitude …	Positive	3,068
Erman Akkus @Erman_Akkus	📢DESTINY-Gastric04 ➡️Phase-3 ➡️HER2-positive gastric/GEJ adenocarcinoma ➡️2L ➡️Trastuzumab-deruxtecan VS. ramicurumab-paclitaxel ✅Statistically significant and clinically meaningful improvement in OS with T-Dxd 👉https://t.co/0DcO1KgCHT @…	Positive	2,510
Toni Choueiri, MD @DrChoueiri	JUST IN: T-DXd has demonstrates an OS benefit in second-line treatment of HER2-positive metastatic gastric cancer, as announced in the ph3 DESTINY-Gastric04 trial. The study has been unblinded. ⁦@DaiichiSankyoUS⁩	Positive	2,379
Yüksel Ürün @DrYukselUrun	DESTINY-Gastric04 trial shows trastuzumab deruxtecan significantly improves overall survival in 2L HER2+ metastatic gastric cancer vs. standard chemo. @OncoAlert https://t.co/QonUsTCN0c	Neutral	2,150
Jun Gong @jgong15	rand PhIII DESTINY-Gastric04 of #2L T-DXd vs ram/taxol in HER2+ adv #GC/GEJA (84% IHC 3+) ➡️ OS 14.7 vs 11.4 mos, PFS 6.7 vs 5.6 mos, ORR 44.3% vs 29.1% in favor of #2L T-DXd, 14% ILD (most G1-2) w/T-DXd. Ready for de-escalation to 5.4 mg/k…	Neutral	1,888
Oncology Brothers @OncBrothers	5. #DESTINYGastric04: Ph III, TDXd (6.4mg/kg) vs Pac + Ramucirumab in 2L HER2+ GEJ/Gastric. - mPFS: 6.7 vs 5.6 mos (HR: 0.74) - mOS: 14.7 vs 11.4 mos (HR: 0.70) - ORR: 44.3% vs 29.1% 6/8 https://t.co/xfDBXrrTa0	Neutral	1,318
Sharlene Gill, MD, MPH, MBA, FASCO @GillSharlene	#ASCO25 @ASCO DESTINY Gastric04 Ph3 2L TDXd vs RAM/PTX in HER2+ GC/GEJ adeno N=494, 40% Asia, 80%. IHC 3+ ➡️ OS 14.7m v 11.4m (HR0.70, p=0.044)) ➡️ ORR 44 v 29% No new safety signals 🇨🇦 approved with +CDA ‼️@CDNCancerTrials open GA.4 tri…	Neutral	1,143
Mustafa Özdoğan, MD @ozdogan_md	🚨 New 2nd-line standard in HER2+ gastric cancer? 🔥 The DESTINY-Gastric04 trial shows T-DXd significantly improves OS (14.7 vs 11.4 mo) and ORR (44.3% vs %29.1) vs RAM+PTX. 📉 ILD risk remains—but mostly low-grade. 👨‍⚕️ Presented by @Kohei…	Nuanced	981
Mario Balsa @MarioBalsaMD	🚨Breaking from #ASCO25 — DESTINY-Gastric04 T-DXd outperforms RAM+PTX in 2L HER2+ advanced G/GEJ cancer: 🎯mOS: 14.7 vs 11.4 mo (HR: 0.70, p=0.004) ▪️mPFS: 6.7 vs 5.6 mo ▪️cORR: 44.3% vs 29.1% ▪️DCR: 91.9% vs 75.9% A new standard? Eureka, …	Positive	924
Tamara Sauri @TamaraSN2	Networking with Global Daiichi Sankyo at #ESMOWGI2023 reviewing data #DESTINYGastric04 and more things🎯 T-DXd probably new standard treatment in 2L HER2ampl Gastric Cancer standard treatment	Positive	868
Ryan Huey, MD, MS @ryanhuey	Dr. Shitara with DESTINY-Gastric04, 2L T-DxD vs chemo in HER2+ GC/GEJA: mOS 14.7 vs 11.4 months (HR 0.7). PFS 6.7 vs 5.6 months (0.74) Only 21% of pts in ram/taxol arm received subsequent T-DxD. #ASCO25	Neutral	767
Bassam Sonbol @sonbol_bassam	"Gr8 to see the study confirming the benefit! Already approved & SOC in 2L GEA based on 3L+ GastricCancer (Asian) Gastric01 & 2L (single arm; Western) #Gastric02. Intrigued to see final results, esp. for HER2+2 FISH+ (see below). #Oncology …	Neutral	748
Alberto Pimentel MD @ALBERTO87050566	Terrific information 👍🏻. The question is: ¿who currently treats their patients with HER2 over-amplified/over-expressed with paclitaxel plus ramucirumab?	Neutral	542
Dr. Estela Rodriguez @Latinamd	Great overview of #ASCO25 GI Cancer Highlights by @DrBonillaOnc #ASCODirect Puerto Rico ✅ #CHALLENGE ✅ #ATOMIC ✅ #BREAKWATER ✅ #MATTERHORN ✅ #DESTINYGastric04 @TotalHealthConf	Positive	521
Shanda Blackmon, MD, MPH @ShandaBlackmon	DESTINY-Gastric04 trial for eso GEJxn ca and gastric ca patients demonstrated superior OS of T-Dxd 14.7 mo vs RAM +PTX ⁦@ASCO⁩ #ASCO25	Neutral	512
Byung-June Park @onco_park	2L HER2+ metastatic Gastric Cancer ENHERTU® Demonstrated Statistically Significant and Clinically Meaningful Improvement in Overall Survival in Patients with HER2 Positive Metastatic Gastric Cancer at Interim Analysis of DESTINY-Gastric04 P…	Positive	488
cinta hierro carbo @chierrocarbo	📢Practice-changing in 2L HER2+ GOJ/GC: DESTINY-Gastric04 trial 👁️T-Dxd vs paclitaxel+ramucirumab 🎯14.7 vs 11.4 m; HR 0.70 (p=0.004) ⚠️ILD/pneumonitis in 14% (mostly G1/2) 👣an exciting future to walk through with studies testing T-Dxd and z…	Positive	267
Jean Emmanuel Kurtz @PrJEKurtz	All right. Wait for numbers. Clinically meaningful sounds good, but wait !	Nuanced	145
Ippokratis Korantzis, Medical Oncologist, MD, PhD @newsincancer	ENHERTU® Demonstrated Statistically Significant and Clinically Meaningful Improvement in Overall Survival in Patients with HER2 Positive Metastatic Gastric Cancer at Interim Analysis of #DESTINYGastric04 Phase 3 Trial -	Positive	129
Daniel Acosta Eyzaguirre @DanielAcostaEy1	📢🚨DESTINY-Gastric04 positive trial! Waiting for detailed results! https://t.co/Zbbt8q5ZaD	Positive	118
Santhosh Ambika @RenoHemonc	Unlike breast ,benefit disproportionality driven by 3+	Neutral	19

See full DESTINY-Gastric04 conference coverage & trial data →

Regulatory

ENHERTU® — FDA status

FDA APPROVEDENHERTU® (trastuzumab deruxtecan) is FDA-approved across multiple HER2-driven cancers — including first-line (with pertuzumab) and later-line HER2-positive metastatic breast cancer, HR+/HER2-low and HER2-ultralow metastatic breast cancer, neoadjuvant and adjuvant HER2-positive early breast cancer, and HER2-positive gastric/GEJ cancer, plus HER2-mutant NSCLC and HER2 IHC 3+ solid tumors under accelerated approval. For the full, current list of FDA indications and prescribing information, see enhertu.com or FDA label (DailyMed). KOL Pulse indexes the physician conversation; the label is owned and maintained by the manufacturer.

Frequently Asked

ENHERTU® sentiment — FAQ

DESTINY-Breast09

What do oncologists think of the DESTINY-Breast09 trial (ENHERTU®)?

Across 44 verified physician voices in KOL Pulse's index for DESTINY-Breast09, 43% expressed positive sentiment, 21% were nuanced (praising the result while flagging a caveat), 36% were neutral, and 0% were critical. Positive voices highlight the progression-free-survival benefit of moving trastuzumab deruxtecan into the first-line HER2-positive setting in combination with pertuzumab; nuanced and critical voices flag overall-survival maturity, induction-vs-maintenance sequencing, and cumulative toxicity (including interstitial lung disease) of earlier use.

Where can I find the DESTINY-Breast09 trial data for ENHERTU® (trastuzumab deruxtecan)?

DESTINY-Breast09 is registered as NCT04784715 and studied ENHERTU® (trastuzumab deruxtecan) in 1L HER2-positive metastatic breast cancer (T-DXd + pertuzumab). For the full DESTINY-Breast09 trial data and conference coverage, see the KOL Pulse DESTINY-Breast09 trial profile at kolpulse.com/kol-pulse-trial-profile-destinybreast09.

DESTINY-Breast06

What do oncologists think of the DESTINY-Breast06 trial (ENHERTU®)?

Across 41 verified physician voices in KOL Pulse's index for DESTINY-Breast06, 34% expressed positive sentiment, 12% were nuanced (praising the result while flagging a caveat), 47% were neutral, and 7% were critical. Positive voices highlight extending trastuzumab deruxtecan to HER2-low and HER2-ultralow disease, redefining who is 'HER2-targetable' in the post-endocrine setting; nuanced and critical voices flag HER2-low/ultralow assay reproducibility and patient selection, and how it sequences against endocrine-based and other post-endocrine options.

Where can I find the DESTINY-Breast06 trial data for ENHERTU® (trastuzumab deruxtecan)?

DESTINY-Breast06 is registered as NCT04494425 and studied ENHERTU® (trastuzumab deruxtecan) in HR+/HER2-low and HER2-ultralow metastatic breast cancer after endocrine therapy. For the full DESTINY-Breast06 trial data and conference coverage, see the KOL Pulse DESTINY-Breast06 trial profile at kolpulse.com/kol-pulse-trial-profile-destinybreast06.

DESTINY-Breast03

What do oncologists think of the DESTINY-Breast03 trial (ENHERTU®)?

Across 3 verified physician voices in KOL Pulse's index for DESTINY-Breast03, 0% expressed positive sentiment, 33% were nuanced (praising the result while flagging a caveat), 67% were neutral, and 0% were critical. Positive voices highlight the practice-changing head-to-head superiority of trastuzumab deruxtecan over T-DM1 that made it the preferred second-line HER2-positive standard; nuanced and critical voices flag interstitial lung disease monitoring and the durability/overall-survival follow-up as the drug moved to earlier lines.

Where can I find the DESTINY-Breast03 trial data for ENHERTU® (trastuzumab deruxtecan)?

DESTINY-Breast03 is registered as NCT03529110 and studied ENHERTU® (trastuzumab deruxtecan) in 2L+ HER2-positive metastatic breast cancer (T-DXd vs T-DM1). For the full DESTINY-Breast03 trial data and conference coverage, see the KOL Pulse DESTINY-Breast03 trial profile at kolpulse.com/kol-pulse-trial-profile-destinybreast03.

DESTINY-Breast11

What do oncologists think of the DESTINY-Breast11 trial (ENHERTU®)?

Across 36 verified physician voices in KOL Pulse's index for DESTINY-Breast11, 39% expressed positive sentiment, 17% were nuanced (praising the result while flagging a caveat), 33% were neutral, and 11% were critical. Positive voices highlight bringing trastuzumab deruxtecan into curative-intent neoadjuvant therapy with an anthracycline-free backbone and improved pathologic response; nuanced and critical voices flag which patients truly need escalation, event-free-survival maturity, and avoiding overtreatment/toxicity in early-stage disease.

Where can I find the DESTINY-Breast11 trial data for ENHERTU® (trastuzumab deruxtecan)?

DESTINY-Breast11 is registered as NCT05113251 and studied ENHERTU® (trastuzumab deruxtecan) in Neoadjuvant HER2-positive Stage II/III early breast cancer. For the full DESTINY-Breast11 trial data and conference coverage, see the KOL Pulse DESTINY-Breast11 trial profile at kolpulse.com/kol-pulse-trial-profile-destinybreast11.

DESTINY-Breast05

What do oncologists think of the DESTINY-Breast05 trial (ENHERTU®)?

Across 26 verified physician voices in KOL Pulse's index for DESTINY-Breast05, 23% expressed positive sentiment, 8% were nuanced (praising the result while flagging a caveat), 65% were neutral, and 4% were critical. Positive voices highlight carrying the trastuzumab deruxtecan benefit into the adjuvant residual-disease setting as a successor to post-neoadjuvant T-DM1; nuanced and critical voices flag interstitial lung disease in a curative population, duration of therapy, and long-term event-free-survival maturity.

Where can I find the DESTINY-Breast05 trial data for ENHERTU® (trastuzumab deruxtecan)?

DESTINY-Breast05 is registered as NCT04622319 and studied ENHERTU® (trastuzumab deruxtecan) in Adjuvant HER2-positive early breast cancer with high-risk residual disease. For the full DESTINY-Breast05 trial data and conference coverage, see the KOL Pulse DESTINY-Breast05 trial profile at kolpulse.com/kol-pulse-trial-profile-destinybreast05.

DESTINY-Gastric04

What do oncologists think of the DESTINY-Gastric04 trial (ENHERTU®)?

Across 26 verified physician voices in KOL Pulse's index for DESTINY-Gastric04, 50% expressed positive sentiment, 8% were nuanced (praising the result while flagging a caveat), 42% were neutral, and 0% were critical. Positive voices highlight a confirmatory second-line overall-survival benefit for trastuzumab deruxtecan in HER2-positive gastric/GEJ cancer versus ramucirumab + paclitaxel; nuanced and critical voices flag toxicity (including interstitial lung disease) in gastric patients and how it sequences against other later-line gastric options.

Where can I find the DESTINY-Gastric04 trial data for ENHERTU® (trastuzumab deruxtecan)?

DESTINY-Gastric04 is registered as NCT04704934 and studied ENHERTU® (trastuzumab deruxtecan) in 2L HER2-positive gastric/GEJ adenocarcinoma (T-DXd vs ramucirumab + paclitaxel). For the full DESTINY-Gastric04 trial data and conference coverage, see the KOL Pulse DESTINY-Gastric04 trial profile at kolpulse.com/kol-pulse-trial-profile-destinygastric04.

Regulatory

Is ENHERTU® (trastuzumab deruxtecan) FDA approved?

ENHERTU® is FDA-approved. KOL Pulse organizes this page by clinical trial and links out to the manufacturer's brand site and the FDA label for the full, current list of FDA indications and prescribing information — the label is owned and updated by the manufacturer, so we point to it rather than reproducing it.

Methodology

How this index is built

KOL Pulse indexes verbatim posts from verified oncology physicians and rolls sentiment up per clinical trial. Each physician is counted once per trial, at their highest-reach post. Sentiment is classified from the verbatim text (positive / nuanced / neutral / critical), where "nuanced" marks a voice that praises the result while flagging a substantive caveat (immature overall survival, toxicity, or trial-design/selection concerns). Institutional, media, finance, and non-physician accounts are excluded from the denominator. Quotes are reproduced verbatim and attributed to the physician's public post. KOL Pulse organizes this page by clinical trial — the maintainable unit — and links out to the manufacturer's brand site and the FDA label for the full indication list, which the manufacturer owns and updates. Trial efficacy figures are held for medical-expert verification before publication. This page reports the physician conversation; it is not medical advice and does not endorse any product.